Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated with infrequent but lethal myocarditis, for which management remains uncertain. Abatacept, a CTLA-4 fusion protein targeting CD86 on antigen presenting cells and leading to global T-cell anergy, has been describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Lee S, Bretagne, Marie, Arrondeau, Jennifer, Zahr, Noel, Ederhy, Stephane, Abbar, Baptiste, Pinna, Bruno, Allenbach, Yves, Mira, Jean-Paul, Moslehi, Javid, Rosenzwajg, Michelle, Salem, Joe-Elie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984056/
https://www.ncbi.nlm.nih.gov/pubmed/35383117
http://dx.doi.org/10.1136/jitc-2022-004699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984056/
https://www.ncbi.nlm.nih.gov/pubmed/35383117
http://dx.doi.org/10.1136/jitc-2022-004699

Ejemplares similares